Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Atomera Incorporated (ATOM) vs BioNano Genomics Inc (BNGO) Price & Performance

Atomera IncorporatedTrade
BioNano Genomics IncTrade

Price performance (Past 24H)

Key statistics

Atomera Incorporated vs BioNano Genomics Inc — how do they compare? Atomera Incorporated trades at $5.57 (market cap $209.56M), while BioNano Genomics Inc trades at $1.18 (market cap $13.31M). The key difference: Atomera Incorporated is far larger — about 15.7× BioNano Genomics Inc's market cap, and Atomera Incorporated is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

ATOMBNGO
Market Cap
$209.56M$13.31M
Sector
TechnologyHealth
52-Week High
$12.11$4.92
52-Week Low
$1.99$1.06
Enterprise Value
$172.37M$15.92M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Atomera Incorporated

ATOM trades at $5.48, up 3.1% today, but faces significant fundamental challenges with a P/S ratio of 797.66 and deeply negative profitability metrics including a -78.7% gross margin and -9,742% net income margin. The company has missed earnings expectations for three consecutive quarters while technical indicators show bearish momentum with RSI signaling overbought conditions at 78.05. Recent news highlights progress in semiconductor technology licensing but financial performance remains weak.

Despite unanimous analyst buy ratings, ATOM presents high-risk exposure due to substantial losses, negative cash flow, and elevated valuation multiples. The semiconductor licensing business shows technological promise but requires significant revenue acceleration to justify current valuation. Near-term catalysts depend on commercial adoption breakthroughs while downside risk remains elevated given current financial metrics.

BioNano Genomics Inc

BNGO trades at $1.16, up 5.45% today, with a bullish technical signal from moving averages. The company shows improving financial trends with revenue stabilizing around $29M annually and narrowing losses from -$232M in 2023 to -$26M in 2025. Recent earnings beats and positive news flow around optical genome mapping adoption support momentum.

While BNGO demonstrates operational improvement and analyst support (57% buy ratings), the stock faces significant risks including persistent negative profitability, cash burn requiring ongoing financing, and competitive pressures in genomic technology. The current valuation appears attractive on P/S and P/B metrics but reflects the company's pre-profitability stage.

Returns comparison

Trailing returns across standard periods

About Atomera Incorporated

Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.

Read more on ATOM

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO